###### Key messages

What is the key question?
=========================

-   What are the age and sex-specific absolute and relative risks of developing smoking-related second and higher order primary cancers following lung cancer?

What is the bottom line?
========================

-   Our population-based approach shows that lung cancer survivors, particularly women, have increased the incidence of smoking-related primary cancers for at least a decade from the time of their first primary lung cancer diagnosis, with those aged 50--79 at first diagnosis at particularly high risk.

Why read on?
============

-   With improving lung cancer survival rates consideration should be given to extending lung cancer follow-up from 5 years to 10 years and to undertaking surveillance for other smoking-related cancers including head and neck, laryngeal and oesophageal squamous cell carcinoma.

Introduction {#s1}
============

Five-year survival of patients with lung cancer has doubled in England during the past 15 years leading to increasing numbers of survivors.[@R1] Lung cancer survivors are thought to be at an increased risk of second primary cancer (SPC).[@R3] However, neither the way in which incidence of subsequent malignancy changes during follow-up nor patient characteristics associated with increased risk of SPC are well understood. We have estimated the incidence of smoking-related second and higher order primary cancers following a primary diagnosis of lung cancer to determine which groups are at higher risk and evaluate how incidence changes over time following diagnosis. We have focused on cancers of the lung, larynx, head and neck, oesophagus (squamous cell carcinoma) and urinary bladder as these cancers have the largest proportion of deaths attributable to cigarette smoking.[@R7] We assessed the incidence of developing an SPC at different time points after initial diagnosis to inform clinicians about optimal follow-up periods and surveillance regimens after lung cancer treatment with curative intent.

Methods {#s2}
=======

Smoking-related primary cancers {#s2a}
-------------------------------

Data from the National Cancer Registration and Analysis Service of Public Health England (the organisation responsible for cancer registration in England) provided information on first, second and higher order smoking-related primary cancers diagnosed in English residents aged 30--99 between 1 January 2000 and 31 December 2014. This included all diagnoses of the lung (ICD-10, C33--C34), bladder (C67), oesophageal squamous cell carcinoma (OSCC) (C15, morphology codes 8070--8074, 8094, 8123, 8560), laryngeal (C32) and head and neck cancers (C00--C14, C31). The cancer registry captures at least 98% of primary cancer diagnoses in England[@R8] and records multiple primary cancers following International Agency for Research on Cancer and European Network of Cancer Registries' rules.[@R9] Cases classified as recurrence of first primary lung cancer were excluded. Data were available on tumour type (site, morphology), month of diagnosis as well as patient information including age at diagnosis, sex, income deprivation quintile and vital status (whether a patient was alive, dead or lost to follow-up).[@R10] Lung cancers were divided into small cell lung cancer (SCLC) and non-SCLC (NSCLC), and NSCLC was split into adenocarcinoma, squamous cell carcinoma, other NSCLC, carcinoid and unspecified lung (online [supplementary appendix 1 table 1](#SP1){ref-type="supplementary-material"}).
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Estimating expected incidence of smoking-related primary cancers {#s2b}
----------------------------------------------------------------

To evaluate whether lung cancer survivors were at an increased risk of SPC compared with those with no diagnosis of lung cancer, we estimated the number of cancers we would expect in people without lung cancer (online [supplementary appendix 2 figure 2](#SP1){ref-type="supplementary-material"}). We obtained midyear population estimates for England from 2000 to 2014 from the Office for National Statistics and matched these with first primary cancers in our dataset to calculate the expected age-sex-year-specific incidence rates.[@R11] We matched these rates with person-years of follow-up in the cancer registry dataset stratified by sex, attained age and attained year. We multiplied the person-years of follow-up by the expected age-sex-year-specific incidence rates to calculate the number of expected cancers. We compared the number of observed and expected cancers to calculate standardised incidence rate ratios (SIRs).

Statistical analysis {#s2c}
--------------------

### Analysis cohort {#s2c1}

After restriction (online [supplementary appendix 2 figure 1](#SP1){ref-type="supplementary-material"}), the analysis cohort included 490 328 patients with first primary lung cancer. Most patients (489 740, 99.9%) had complete survival follow-up to death or censoring at 31 December 2014. Follow-up for the remaining 588 patients was censored on the day they were last known to be alive.

Our analyses exclude primary cancers diagnosed within 6 months of the first primary cancer as such tumours were deemed likely to represent 'synchronous' diagnoses.

### Descriptive analysis {#s2c2}

We described absolute incidence rates and SIRs for the cohort from 6 months to 10 years follow-up, including by sex, age at diagnosis and deprivation group, as well as by the site of the SPC. We provide a brief summary of the incidence of subsequent smoking-related SPC up to 10 years from diagnosis for those diagnosed in 2000--2004, with complete follow-up, as other descriptive results may be affected by variable follow-up periods.

The choice to limit at 10 years follow-up was informed by the results of Kaplan-Meier survival analyses, presented in online [supplementary appendix 4 figure 1](#SP1){ref-type="supplementary-material"}.

### Describing how risk changes over follow-up {#s2c3}

We investigated how absolute incidence rates (second and higher order primary cancers diagnosed per 100 000 patient-years) and SIRs changed during follow-up. We plotted age-sex-specific incidence rate and SIR against months of follow-up and modelled how the incidence rate or SIR changed over time using Poisson models with patient-years (incidence rate) or expected cancers (SIR) as exposure. We modelled elapsed follow-up time using restricted cubic splines allowing us to avoid the disadvantages of categorisation while providing for potentially non-linear associations between elapsed follow-up and SPC risk.[@R12] Exploratory modelling guided the choice and number of knots and the interaction terms used in the model. The final models included pairwise interactions between age and follow-up, sex and follow-up, and age and sex, and parameterised follow-up using splines with knots at 6, 12, 60 and 120 months. Further interaction terms were not included as they decreased model fit measured using the Akaike information criterion.[@R14] We used the same approach to evaluate changes in SIR over follow-up by the site of SPC and by the morphology of first primary lung cancer, removing age at diagnosis and sex from the model. Results were not sensitive to the exact knot locations (online [supplementary appendix 3 figure 1](#SP1){ref-type="supplementary-material"}).

### Describing how risk changes by year of first primary lung cancer diagnosis {#s2c4}

We extended our initial approach to evaluate how the risk of SPC changed during different study periods, limiting observations to 6--60 months of follow-up. Based on exploratory analyses, we split SPC into second primary lung cancers and other smoking-related primary cancers. We initially described the observed changes in absolute risk of second primary lung and other smoking-related primary cancers in patients diagnosed with first primary lung cancer in 2005--2009 and 2010--2014 compared with 2000--2004. We then used the Akaike information criterion to select an adjusted model,[@R14] considering patient age, sex, deprivation and elapsed follow-up (modelled as above using restricted cubic splines with knots at 6, 12 and 60 months follow-up) and all two-way interactions. This provided a check that apparent differences were not explained by changes in patient casemix or improvements in survival.

Results {#s3}
=======

Description of analysis cohort {#s3a}
------------------------------

Between 2000 and 2014, 490 328 patients were diagnosed with first primary lung cancer ([table 1](#T1){ref-type="table"}). We have a priori focused on the 213 245 patients (43%) surviving 6 months after diagnosis, contributing 335 436 patient-years of follow-up ([table 1](#T1){ref-type="table"}; online [supplementary appendix 4 figure 1](#SP1){ref-type="supplementary-material"}). The median follow-up was 10 months per patient (IQR 4--28 months). Despite low survival rates, 4710 patients diagnosed in 2004 or before were still alive at 10 years follow-up ([table 1](#T1){ref-type="table"}). Survival rates were higher for women than men and for younger than older patients (online [supplementary appendix 4 figure 1](#SP1){ref-type="supplementary-material"}). Lung cancer was more common in patients from more deprived areas and more deprived patients had worse survival.

###### 

Number of patients alive and in follow-up at the start of interval and absolute incidence rate within interval periods within the first 10 years after diagnosis with first primary lung cancer, by patient and tumour characteristics. The period 'diagnosis to 6 months' was discarded from all other analyses

                                     Diagnosis to 6 months   6--12 months   1--5 years       5--10 years      10 years                                                                                                                      
  ---------------------------------- ----------------------- -------------- ---------------- ---------------- ---------- --------------- -------------- --------- --------------- -------------- -------- ---------------- ---------------- ------
  Overall                                                    490 328        1338             (1276 to 1402)   213 245    399             (358 to 443)   128 128   683             (647 to 720)   19 280   1184             (1093 to 1280)   4710
  Subsite of first primary cancer    Small cell carcinoma    57 179         534              (427 to 660)     26 896     213             (133 to 322)   13 224    495             (388 to 622)   1275     995              (697 to 1378)    335
  Adenocarcinoma                     100 395                 1461           (1330 to 1601)   55 363           422        (342 to 514)    36 524         738       (672 to 809)    6063           1275     (1106 to 1461)   1394             
  Squamous cell carcinoma            97 253                  1672           (1532 to 1822)   56 077           552        (461 to 656)    35 960         864       (790 to 943)    6120           1398     (1227 to 1586)   1568             
  Other non-small cell lung cancer   75 505                  1226           (1083 to 1382)   35 004           295        (212 to 400)    20 008         590       (505 to 686)    2826           1310     (1062 to 1598)   592              
  Carcinoid                          3422                    1930           (1260 to 2827)   3074             539        (233 to 1061)   2834           146       (75 to 255)     1368           253      (126 to 453)     484              
  Unspecified lung                   156 574                 1341           (1212 to 1479)   36 831           332        (244 to 441)    19 578         515       (428 to 614)    1628           853      (594 to 1187)    337              
  Age at diagnosis                   30--49                  13 890         925              (667 to 1251)    8500       452             (258 to 733)   5484      262             (172 to 381)   1429     340              (194 to 551)     541
  50--59                             51 944                  1075           (921 to 1247)    28 981           283        (196 to 396)    18 168         579       (497 to 670)    3728           1006     (832 to 1206)    1203             
  60--69                             125 462                 1412           (1293 to 1538)   64 156           404        (331 to 488)    40 145         746       (681 to 816)    6898           1396     (1234 to 1574)   1756             
  70--79                             173 884                 1552           (1440 to 1670)   73 690           426        (355 to 506)    44 198         766       (701 to 836)    5934           1339     (1160 to 1538)   1108             
  80--99                             125 148                 1104           (983 to 1234)    37 918           418        (320 to 537)    20 133         596       (502 to 703)    1291           1037     (671 to 1530)    102              
  Sex                                Male                    278 006        1540             (1452 to 1633)   1 17 308   460             (401 to 526)   68 811    806             (752 to 863)   9814     1316             (1183 to 1460)   2437
  Female                             212 322                 1081           (998 to 1169)    95 937           325        (271 to 387)    59 317         549       (503 to 599)    9466           1045     (924 to 1177)    2273             
  Deprivation quintile               1-least deprived        68 084         1335             (1175 to 1512)   31 084     378             (279 to 502)   19 002    601             (516 to 695)   3017     1033             (828 to 1273)    777
  2                                  85 982                  1266           (1126 to 1419)   38 313           362        (273 to 469)    22 840         639       (558 to 729)    3426           1195     (983 to 1440)    859              
  3                                  98 660                  1372           (1234 to 1520)   42 644           451        (356 to 562)    25 703         649       (572 to 734)    3867           1211     (1011 to 1438)   947              
  4                                  111 788                 1363           (1234 to 1503)   47 560           354        (275 to 448)    28 445         685       (609 to 768)    4239           1074     (894 to 1280)    1024             
  5-most deprived                    125 814                 1339           (1218 to 1470)   53 644           437        (353 to 534)    32 138         790       (713 to 874)    4731           1354     (1159 to 1572)   1103             
  Year of diagnosis                  2000                    31 289         750              (573 to 966)     12 610     258             (137 to 441)   7335      432             (324 to 565)   1615     857              (640 to 1124)    918
  2001                               30 924                  743            (566 to 959)     12 567           316        (181 to 513)    7371           714       (573 to 880)    1632           977      (746 to 1258)    911              
  2002                               29 999                  885            (689 to 1121)    12 386           301        (169 to 497)    7332           511       (392 to 656)    1591           1008     (771 to 1294)    899              
  2003                               30 071                  670            (501 to 879)     12 352           477        (306 to 710)    7484           519       (402 to 661)    1749           899      (684 to 1159)    981              
  2004                               30 543                  971            (767 to 1211)    12 957           342        (202 to 540)    7859           497       (384 to 632)    1763           1506     (1225 to 1832)   1001             
  2005                               30 850                  1124           (906 to 1379)    13 244           258        (141 to 433)    8126           546       (430 to 683)    1867           1438     (1160 to 1761)   --               
  2006                               32 075                  857            (672 to 1077)    13 841           389        (244 to 589)    8468           671       (544 to 819)    1940           1371     (1080 to 1716)   --               
  2007                               32 236                  1207           (987 to 1461)    14 332           426        (275 to 628)    8831           700       (575 to 845)    2152           1122     (840 to 1468)    --               
  2008                               32 994                  1466           (1225 to 1739)   14 837           311        (187 to 486)    9270           662       (543 to 798)    2290           1496     (1103 to 1984)   --               
  2009                               33 244                  1160           (951 to 1402)    15 509           297        (179 to 463)    9877           853       (726 to 997)    2681           1570     (984 to 2377)    --               
  2010                               33 772                  1754           (1497 to 2043)   15 900           271        (161 to 428)    10 340         771       (649 to 909)    --                                       --               
  2011                               34 651                  1710           (1460 to 1989)   16 802           454        (310 to 640)    11 070         803       (672 to 953)    --                                       --               
  2012                               35 838                  2277           (1995 to 2587)   18 068           612        (450 to 814)    12 276         962       (802 to 1145)   --                                       --               
  2013                               35 900                  1771           (1524 to 2046)   18 351           617        (455 to 818)    12 489         843       (621 to 1117)   --                                       --               
  2014                               35 942                  2150           (1848 to 2488)   9489             602        (337 to 994)    --                                       --                                       --               

Around 1.1% (2328 of 213 245) of patients alive at 6 months had SPCs during follow-up, some of whom had higher order (ie, third or fourth) primary cancers as well. Restricting to patients diagnosed in 2000--2004 who survived to 6 months and have 10 years complete follow-up gives similar results.

Overall incidence of second and higher order primary cancers {#s3b}
------------------------------------------------------------

Over the entire length of follow-up, SIRs for second and higher order primary cancer were highest for those aged 30--49 (SIR 3.4, 95% CI 2.6 to 4.4) or 50--59 at diagnosis (SIR 2.7, 2.5 to 3.1), for women (SIR 2.0, 1.9 to 2.1) and for the most deprived patients (SIR 1.8, 1.7 to 2.0) ([table 2](#T2){ref-type="table"}). Patients whose first primary lung cancer was adenocarcinoma (SIR 1.9, 1.7 to 2.0) or squamous cell carcinoma (SIR 1.8, 1.6 to 1.9) were at highest risk of SPC, while those with carcinoid tumours were not at increased risk (SIR 0.7, 0.5 to 1.1) ([table 2](#T2){ref-type="table"}; online [supplementary appendix 4 figure 4](#SP1){ref-type="supplementary-material"}).

###### 

Observed and expected second and higher order primary cancers over the entire 335 436 patient-years of follow-up from 6 months after diagnosis to 10 years follow-up or the 31 December 2014, overall, by subsite of first primary lung cancer and by patient characteristics. Italics denotes the lung sub-sites

                                         Observed SPCs          Expected SPCs   Absolute incidence rate per 100 000 person-years   Standardised incidence rate ratio                                       
  -------------------------------------- ---------------------- --------------- -------------------------------------------------- ----------------------------------- ------------------ ---------------- ----------------
  Overall                                                       2313            1491.9                                             689.6                               (661.7 to 718.2)   1.55             (1.49 to 1.61)
  Subsite of first primary lung cancer   Small cell carcinoma   131             109.0                                              455.3                               (380.7 to 540.2)   1.20             (1.00 to 1.43)
  Adenocarcinoma                         759                    407.0           752.4                                              (699.8 to 807.9)                    1.86               (1.73 to 2.00)   
  Squamous cell carcinoma (SCC)          873                    497.9           882.8                                              (825.2 to 943.3)                    1.75               (1.64 to 1.87)   
  Other NSCLC                            312                    223.0           619.4                                              (552.6 to 692.1)                    1.40               (1.25 to 1.56)   
  Carcinoid                              31                     41.7            219.4                                              (149.1 to 311.4)                    0.74               (0.51 to 1.06)   
  Unspecified lung                       207                    213.2           488.3                                              (424.0 to 559.5)                    0.97               (0.84 to 1.11)   
  Site of SPC                            Lung                   1460            993.8                                              435.3                               (413.2 to 458.2)   1.47             (1.39 to 1.55)
   *Small cell carcinoma*                142                    94.3            42.3                                               (35.7 to 49.9)                      1.51               (1.27 to 1.78)   
   *NSCLC*                               1318                   899.5           392.9                                              (372.0 to 414.7)                    1.47               (1.39 to 1.55)   
    *Adenocarcinoma*                     485                    187.8           144.6                                              (132.0 to 158.0)                    2.58               (2.36 to 2.82)   
    *Squamous cell carcinoma*            400                    190.9           119.2                                              (107.8 to 131.5)                    2.10               (1.90 to 2.31)   
    *Other NSCLC*                        216                    143.5           64.4                                               (56.1 to 73.6)                      1.51               (1.31 to 1.72)   
    *Carcinoid*                          13                     4.4             3.9                                                (2.1 to 6.6)                        2.98               (1.59 to 5.10)   
    *Unspecified lung*                   204                    372.9           60.8                                               (52.8 to 69.8)                      0.55               (0.47 to 0.63)   
  Bladder                                397                    299.9           118.4                                              (107.0 to 130.6)                    1.32               (1.20 to 1.46)   
  Oesophageal SCC                        124                    52.1            37.0                                               (30.7 to 44.1)                      2.38               (1.98 to 2.84)   
  Laryngeal                              122                    43.5            36.4                                               (30.2 to 43.4)                      2.81               (2.33 to 3.35)   
  Head and neck                          210                    102.6           62.6                                               (54.4 to 71.7)                      2.05               (1.78 to 2.34)   
  Age at diagnosis                       30--49                 59              17.5                                               316.1                               (240.6 to 407.8)   3.38             (2.57 to 4.35)
  50--59                                 332                    121.0           608.3                                              (544.6 to 677.3)                    2.74               (2.46 to 3.05)   
  60--69                                 862                    428.0           779.0                                              (727.8 to 832.7)                    2.01               (1.88 to 2.15)   
  70--79                                 833                    658.9           751.4                                              (701.2 to 804.2)                    1.26               (1.18 to 1.35)   
  80--99                                 227                    266.4           558.1                                              (487.9 to 635.6)                    0.85               (0.74 to 0.97)   
  Sex                                    Male                   1398            1030.7                                             792.7                               (751.7 to 835.4)   1.36             (1.29 to 1.43)
  Female                                 915                    461.1           575.2                                              (538.5 to 613.7)                    1.98               (1.86 to 2.12)   
  Deprivation quintile                   1-least deprived       315             234.4                                              616.1                               (549.9 to 688.0)   1.34             (1.20 to 1.50)
  2                                      391                    273.5           653.7                                              (590.5 to 721.8)                    1.43               (1.29 to 1.58)   
  3                                      464                    303.2           688.4                                              (627.2 to 754.0)                    1.53               (1.39 to 1.68)   
  4                                      492                    325.1           663.9                                              (606.5 to 725.2)                    1.51               (1.38 to 1.65)   
  5 - most deprived                      651                    355.6           784.5                                              (725.4 to 847.2)                    1.83               (1.69 to 1.98)   
  Period of first diagnosis              2000--2004             762             535.8                                              633.3                               (589.2 to 680.0)   1.42             (1.32 to 1.53)
  2005--2009                             941                    575.2           724.6                                              (679.1 to 772.5)                    1.64               (1.53 to 1.74)   
  2010--2014                             610                    380.9           715.4                                              (659.8 to 774.5)                    1.60               (1.48 to 1.73)   
  Elapsed follow-up time                 6--12 months           390             450.9                                              401.4                               (362.5 to 443.3)   0.87             (0.78 to 0.96)
  1--5 years                             1302                   804.8           698.9                                              (661.4 to 737.9)                    1.62               (1.53 to 1.71)   
  5--10 years                            621                    236.2           1194.9                                             (1102.7 to 1292.6)                  2.63               (2.43 to 2.84)   

The most common smoking-related second SPC in this cohort was NSCLC, with 1318 SPCs ([table 2](#T2){ref-type="table"}), primarily adenocarcinoma (485 SPCs) or squamous cell carcinoma (400 SPCs). Bladder cancers were next most common (397 SPCs) followed by head and neck cancers (210 SPCs). However, there were many more laryngeal cancers (SIR 2.8, 95% CI 2.3 to 3.4 and OSCC, SIR 2.4, 95% CI 2.0 to 2.8) than would be expected given incidence rates in the general population, although absolute numbers of these rarer cancers remained small (122 laryngeal and 124 OSCC). Additional results on risk by the site of SPC and by histological type of first primary lung cancer are shown in online [supplementary appendix 4](#SP1){ref-type="supplementary-material"}.

Variation in SPC incidence rates over follow-up {#s3c}
-----------------------------------------------

### Absolute incidence rate {#s3c1}

For patients aged 50--59, 60--69 or 70--79 at first cancer diagnosis, absolute incidence of SPC increased sharply from 6 to 36 months follow-up, and then increased more slowly or remained stable up to 10 years after first cancer ([figure 1](#F1){ref-type="fig"}; online [supplementary appendix 4 table 1](#SP1){ref-type="supplementary-material"}). For example, at 1 year after first primary in men aged 50--59, incidence of SPC was 373 per 100 000 patient-years (95% CI 298 to 468), rising to 718 (578 to 892) at 3 years and 895 (731 to 1096) at 5 years, with the rate at 10 years being 999 (770 to 1296). For younger patients, aged 30--49 at first cancer, incidence rates remained relatively low throughout follow-up. For those aged 80--99, small sample size prevents meaningful long-term examination of SPC risk. In contrast to incidence in the general population, absolute incidence was relatively similar for men and women with NSCLC in most age groups ([figure 1](#F1){ref-type="fig"}).

![Absolute incidence of second and higher order smoking-related primary cancers after lung diagnosis up to 10 years follow-up, by sex and age group.](thoraxjnl-2018-212456f01){#F1}

### Standardised incidence rate ratio {#s3c2}

Patients aged 50--59, 60--69 and 70--79 at first lung cancer diagnosis had a higher-than-expected incidence of smoking-related SPCs from 3 to at least 10 years follow-up, when compared with the general population without lung cancer ([figure 2](#F2){ref-type="fig"}; online [supplementary appendix 4 table 1](#SP1){ref-type="supplementary-material"}). Similar to absolute incidence rates, SIRs increased rapidly from 6 months to 3 years follow-up, but then remained stable or slightly decreased as follow-up continued. For example, the SIR for SPC in men diagnosed with first primary lung cancer aged 50--59 was 1.5 (95% CI 1.2 to 1.8) at 1-year follow-up, increasing to 2.8 (2.3 to 3.5) at 3 years. From 3 years, the SIR decreased slightly but remained higher than the risk in the general population over the entire follow-up (eg, SIR 2.9 at 5 years, 2.6 at 7 years, 2.2 at 10 years, online [supplementary appendix 4 table 1](#SP1){ref-type="supplementary-material"}). Results for those aged 30--49 were highly variable due to the smaller number of cancers than expected in this group, and similarly to the absolute results, meaningful estimation of long-term SPC risk was not possible for those aged 80--99.

![Standardised incidence rate ratios for second and higher order smoking-related primary cancers after lung diagnosis up to 10 years follow-up, by sex and age group. Results for the 30--49 age group are imprecise due to the small number of cancers expected in this group.](thoraxjnl-2018-212456f02){#F2}

Of note, women had higher SIR for smoking-related SPC than men, with SIR for women aged 60--69 at diagnosis being 3.7 (95% CI 3.2 to 4.3) at 5 years follow-up compared with 2.7 (2.4 to 3.1) for men ([figure 2](#F2){ref-type="fig"}). Similar differences were seen in other age groups.

Analysis of different cancer sites revealed that they followed one of three patterns. SIRs for second primary NSCLC and SCLC followed the same pattern as the overall SIRs, beginning with reduced risk but increasing over time ([figure 3](#F3){ref-type="fig"}). SIRs for second primary OSCC, laryngeal cancer and head and neck cancer were elevated across the entire period of follow-up. SIRs for second primary bladder cancer were similar to the general population at the start and end of follow-up, appearing to peak at around 5 years from first primary lung cancer diagnosis, with an SIR at 5 years of 1.8 (95% CI 1.5 to 2.2) ([figure 3](#F3){ref-type="fig"}).

![Standardised incidence rate ratios for second and higher order smoking-related primary cancers after lung diagnosis up to 10 years follow-up, by site of second primary cancer. SCC, squamous cell carcinoma.](thoraxjnl-2018-212456f03){#F3}

### Trends in incidence by year of first primary lung cancer diagnosis {#s3c3}

Patients with more recent first primary lung cancers had higher rates of second primary lung cancers. The incidence rate among patients first diagnosed with lung cancer in 2010--2014 was 715 per 100 000 patient-years (95% CI 660 to 775, [table 2](#T2){ref-type="table"}), higher than among those first diagnosed in 2000--2004 (633, 589 to 680). Given differences in elapsed follow-up, we would have anticipated higher incidence rates among those diagnosed in earlier periods. A more detailed examination, limiting to data between 6 months and 5 years from diagnosis, showed that patients with first primary lung cancer diagnosed in 2010--2014 had double the rate of second primary lung cancers compared with those with first primary diagnosis in 2000--2004 ([figure 4A](#F4){ref-type="fig"}) even though most patients diagnosed in 2010--2014 had not reached 5 years follow-up. In contrast, rates of other smoking-related SPCs remained stable between 2000 and 2014 ([figure 4A](#F4){ref-type="fig"}). Adjusting for patient age, sex, deprivation and elapsed follow-up did not meaningfully change these results ([figure 4B](#F4){ref-type="fig"}).

![Incidence rate ratio for incidence of second primary cancers between 6 and 60 months after first primary lung cancer diagnosis in patients diagnosed with first primary lung cancer in 2005--2009 and 2010--2014 compared with 2000--2004, split into lung cancer, bladder cancer and OSCC, laryngeal, head and neck cancer. Note that most patients diagnosed in 2010--2014 have less than 5 years follow-up in our analysis dataset. OSCC,  oesophageal squamous cell carcinomas.](thoraxjnl-2018-212456f04){#F4}

Discussion {#s4}
==========

There is strong evidence that elevated incidence of second and higher order primary cancers prevails for at least 10 years from first lung cancer diagnosis for patients aged 50--59, 60--69 and 70--79 at first cancer diagnosis. Oesophageal squamous and laryngeal cancers are associated with the greatest excess incidence in lung cancer survivors, although the most frequent type of subsequent malignancy is another lung cancer. We have also identified that the incidence of second primary lung cancer has doubled between 2000--2004 and 2010--2014.

Some recent studies have reported an increased risk of SPC after lung cancer compared with the general population.[@R3] One large cohort study in the USA found the incidence of second primary lung cancer was 1% per patient-year,[@R18] with higher SIRs for women and for younger patients, but did not explore changes in incidence over follow-up from the first primary cancer diagnosis. The majority of other studies had relatively small samples of patients with lung cancer,[@R4] preventing detailed analysis of incidence by patient characteristics or site of SPC. Other work focuses on describing factors associated with higher risk or incidence of SPC among patients with lung cancer.[@R19] These show that risk varies by patient demographics and behaviour and are similar, if not more important, than tumour factors. These studies are broadly in agreement with our results that incidence is highest in patients aged between 50 and 79 at first lung cancer diagnosis with relatively small differences between the main histological subtypes of lung cancer.[@R19] They confirm that continued smoking is associated with higher risk of SPC and adverse outcomes,[@R22] with smoking cessation reducing the incidence of SPC among lung cancer survivors.[@R20]

Our observation that the incidence rate of SPC is lower in the first 2 years of follow-up may be explained by the fact that many tumours, which would have been diagnosed during this period, were diagnosed during initial investigation for lung cancer and were excluded from analysis because we a priori excluded subsequent registrations within the first 6 months from diagnosis of an index smoking-related cancer. The second possibility is that patients with an SPC diagnosed early in follow-up may have been mislabelled as a recurrence of the first primary cancer by their treating clinicians rather than as a true SPC. This is a particularly plausible explanation given that the risk of non-lung SPCs was not reduced at the beginning of follow-up.

Major strengths of our study are its large sample size and population-based nature including all English residents diagnosed with first primary lung cancer between 2000 and 2014. This has allowed us to estimate age-specific and sex-specific incidence for several strata and given sufficient numbers of cancer survivors for meaningful estimation of incidence rates even 10 years after the first lung cancer diagnosis. The flexible parameterisation of follow-up time avoids arbitrary categorisation (and associated loss of statistical power) and enables the assessment of variation in incidence during the time from diagnosis.

The main study limitation is the lack of information on smoking status before and after diagnosis, both of which are moderators of SPC risk.[@R20] Additionally, we have not been able to investigate the impact of tumour factors, such as stage at diagnosis, because this information is incomplete for most study years. Staging information is much more complete for patients diagnosed from 2013 onwards, but these patients do not yet have any meaningful length of follow-up for analysis.

The key implication of this work is that incidence rates for second and higher order primary cancers continue to rise beyond the end of routine specialist 5-year follow-up after an initial lung cancer diagnosis. Given the incidence of SPC varies substantially by age at first diagnosis, consideration should be given to extending routine follow-up from 5 to 10 years, particularly for patients aged 50--79 at first diagnosis. In addition, this evidence can be used to inform lung cancer survivors and their families about the level and nature of risk of other organ cancers; this prognostic information is important for patients and clinicians and may facilitate patient education about possible symptoms of subsequent cancers and, given previous evidence of associations between continued smoking and incidence of further primary cancers, enhance smoking cessation among lung cancer survivors.

Surveillance efforts to promote early detection of subsequent smoking-related primary cancers should focus equally on both men and women. SIRs for second and higher order primary cancers are much higher in female survivors than male survivors. This is due to absolute incidence rates of subsequent primary cancers being similar for both men and women, despite incidence of first primary cancers being higher among men.

Survival rates, particularly for early-stage disease, are expected to improve further which will lead to an increasing population of patients alive 5, 10 or more years from their diagnosis. Our findings suggest a stable increase in the incidence of smoking-related cancers among lung cancer survivors, which will lead to an increasing number of diagnoses of SPC. The observation that the incidence of second primary lung cancer has doubled between 2000--2004 and 2010--2014 indicates that this issue is becoming increasingly important. The reasons behind this rapid change require further investigation but may be related to the changes in incidence of multifocal adenocarcinoma, particularly in women and to an increasing recognition of the issue of SPCs.

The optimal follow-up schedules and investigations to manage this expanding pool of cancer survivors will need to be determined by guideline development groups and policy-makers. Patient and clinician education about risks of SPC will be required to promote prompt diagnosis thereby achieving the best possible longer term outcomes.
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